Technetium Tc-99m ciprofloxacin API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Technetium Tc-99m ciprofloxacin API 374107-43-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Technetium Tc-99m ciprofloxacin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Technetium Tc-99m ciprofloxacin
- Synonyms:
- 99mTc-ciprofloxacin , Infecton , Technetium (99mTc) ciprofloxacin , Technetium Tc 99m ciprofloxacin
- Cas Number:
- 374107-43-4
- DrugBank number:
- DB05488
General Description:
Technetium Tc-99m ciprofloxacin, identified by CAS number 374107-43-4, is a notable compound with significant therapeutic applications. 99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in nuclear medical imaging There is currently controversy around the drug's ability to discriminate between sterile inflammation and bacterial versus nonbacterial infections.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in infectious and parasitic disease (unspecified). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Pharmacodynamics:
Technetium Tc-99m ciprofloxacin exerts its therapeutic effects through: This radiopharmaceutical diagnostic imaging agent is being investigated for its ability to uniquely detect and determine the location of bacterial infection in patients with difficult-to-diagnose signs and symptoms. This may be of use with the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Technetium Tc-99m ciprofloxacin functions by: Ciprofloxacin is a fluoroquinolone antibiotic. The mechanism of action of these fluoroquinolones is not fully understood, but it has been postulated that the interaction of ciprofloxacin with bacterial DNA gyrase (a type II topoisomerase) prevents DNA uncoiling and subsequent DNA synthesis within bacteria. Ciprofloxacin demonstrates a significant antibiotic effect for both gram-negative and gram-positive bacteria in either stationary or growth phases of bacterial replication. However, the addition of the 99mTc atom likely affects the interaction of the ciprofloxacin molecule with the enzyme. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Technetium Tc-99m ciprofloxacin is categorized under the following therapeutic classes: Anti-Bacterial Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors (strong), Cytochrome P-450 Enzyme Inhibitors, Fluoroquinolones, Heterocyclic Compounds, Fused-Ring, Moderate Risk QTc-Prolonging Agents, Organometallic Compounds, QTc Prolonging Agents, Quinolines, Quinolones. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Technetium Tc-99m ciprofloxacin is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
